Motixafortide for MRD Sensitization in AML

Clinical trial NCT07392970 · RECRUITING

Trial details

NCT number: NCT07392970
Sponsor: Washington University School of Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Measurable Residual Disease

Start date: 2026-07-23
Primary completion: 2028-08-02
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.